Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach

De Ridder A, De Graeve D

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Antipsychotic Agents /economics /therapeutic use; Benzodiazepines /economics /therapeutic use; Cost-Benefit Analysis; Female; Humans; Male; Prospective Studies; Regression Analysis; Risperidone /economics /therapeutic use; Schizophrenia /drug therapy /economics

AccessionNumber
22009100903

Date bibliographic record published
02/12/2009